Nvwm LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Nvwm LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 104.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,416 shares of the company's stock after acquiring an additional 7,862 shares during the quarter. Nvwm LLC's holdings in Zoetis were worth $2,512,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of ZTS. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the 3rd quarter worth about $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis in the third quarter worth approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis during the 3rd quarter worth approximately $33,000. Dunhill Financial LLC boosted its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after acquiring an additional 75 shares during the period. Finally, Fortitude Family Office LLC grew its position in Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company's stock valued at $46,000 after acquiring an additional 222 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 2.0 %

Shares of NYSE ZTS traded up $3.41 during mid-day trading on Wednesday, reaching $175.65. 2,084,945 shares of the company were exchanged, compared to its average volume of 2,659,528. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The firm has a 50-day moving average of $169.41 and a 200 day moving average of $179.35. The stock has a market cap of $79.25 billion, a price-to-earnings ratio of 33.02, a P/E/G ratio of 2.72 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business posted $1.36 EPS. The business's revenue for the quarter was up 11.6% compared to the same quarter last year. On average, research analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.14%. Zoetis's payout ratio is 37.59%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Morgan Stanley lowered their price objective on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target for the company. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.